These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 27264674

  • 1. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
    Vuong HG, Kondo T, Oishi N, Nakazawa T, Mochizuki K, Inoue T, Tahara I, Kasai K, Hirokawa M, Tran TM, Katoh R.
    Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
    [Abstract] [Full Text] [Related]

  • 2. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [Abstract] [Full Text] [Related]

  • 3. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, Chung JH, Ki CS, Kim SW.
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [Abstract] [Full Text] [Related]

  • 4. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAFV600E Mutation.
    Lee SE, Hwang TS, Choi YL, Kim WY, Han HS, Lim SD, Kim WS, Yoo YB, Kim SK.
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [Abstract] [Full Text] [Related]

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 6. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.
    Endocr J; 2011 Jun 01; 58(5):381-93. PubMed ID: 21498916
    [Abstract] [Full Text] [Related]

  • 7. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.
    Thyroid; 2014 Aug 01; 24(8):1256-66. PubMed ID: 24798740
    [Abstract] [Full Text] [Related]

  • 8. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT, Chou FF, Wang CH, Lin CL, Chao FP, Chung JC, Huang CC, Wang PW, Cheng JT.
    Thyroid; 2005 Apr 01; 15(4):326-35. PubMed ID: 15876154
    [Abstract] [Full Text] [Related]

  • 9. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
    Nakazawa T, Kondo T, Kobayashi Y, Takamura N, Murata S, Kameyama K, Muramatsu A, Ito K, Kobayashi M, Katoh R.
    Cancer; 2005 Sep 01; 104(5):943-51. PubMed ID: 16015630
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A.
    Thyroid; 2012 Jan 01; 22(1):17-26. PubMed ID: 22150560
    [Abstract] [Full Text] [Related]

  • 11. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A, Zeppa P, Bifulco M, Vitale M.
    Thyroid; 2014 Feb 01; 24(2):254-9. PubMed ID: 23806056
    [Abstract] [Full Text] [Related]

  • 12. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
    Cordioli MI, Moraes L, Bastos AU, Besson P, Alves MT, Delcelo R, Monte O, Longui C, Cury AN, Cerutti JM.
    Thyroid; 2017 Feb 01; 27(2):182-188. PubMed ID: 27849443
    [Abstract] [Full Text] [Related]

  • 13. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 14. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V.
    Endocr Pathol; 2010 Jun 01; 21(2):73-9. PubMed ID: 20012784
    [Abstract] [Full Text] [Related]

  • 15. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.
    Mol Biol (Mosk); 2004 Jun 01; 38(4):642-53. PubMed ID: 15456136
    [Abstract] [Full Text] [Related]

  • 16. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A, Walczyk A, Kowalik A, Pałyga I, Trybek T, Kopczyński J, Kajor M, Chrapek M, Pięciak L, Chłopek M, Góźdź S, Kamiński G.
    Thyroid; 2016 Apr 01; 26(4):543-51. PubMed ID: 26889698
    [Abstract] [Full Text] [Related]

  • 17. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment.
    Boaventura P, Pereira D, Celestino R, Mendes A, Nakasawa T, Teixeira-Gomes J, Sobrinho-Simões M, Soares P.
    Eur J Endocrinol; 2013 Nov 01; 169(5):673-9. PubMed ID: 23966419
    [Abstract] [Full Text] [Related]

  • 18. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
    Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Höög A, Larsson C, Zedenius J.
    Eur J Endocrinol; 2012 Jun 01; 166(6):1049-60. PubMed ID: 22457234
    [Abstract] [Full Text] [Related]

  • 19. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU, Oler G, Nozima BH, Moysés RA, Cerutti JM.
    Eur J Endocrinol; 2015 Oct 01; 173(4):525-40. PubMed ID: 26338373
    [Abstract] [Full Text] [Related]

  • 20. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.
    Mitsutake N, Fukushima T, Matsuse M, Rogounovitch T, Saenko V, Uchino S, Ito M, Suzuki K, Suzuki S, Yamashita S.
    Sci Rep; 2015 Nov 20; 5():16976. PubMed ID: 26584635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.